ERBB3 and breast carcinoma: In patients with breast cancer, either pre-existent dual HER2 mutation or HER2/HER3 co-mutation has been reported to be associated with lack of clinical benefit to neratinib as either a single agent or combined with anti-oestrogen therapy28.